



KARIN STÅLBERG

Sweden

Personal statement

I am a dedicated gynecologic cancer surgeon with a long-standing commitment to improving care for women with gynecologic cancers. Since becoming a specialist in Obstetrics and Gynecology in 2007 and completing my PhD in 2008, I have focused my career on gynecologic cancer surgery, completing subspecialty training in 2013. I currently lead the gynecologic cancer surgery unit at Uppsala University Hospital and have been deeply involved in both clinical and academic leadership. My leadership experience extends beyond medicine as I am chair of our Symphony Orchestra in Uppsala (where I am an active amateur oboist). I am married to a surgeon and proud mother of two grown-up daughters.

My research spans translational science, epidemiology, clinical trials, and quality-of-life studies, with over 60 peer-reviewed publications. At present I supervise five PhD students. I am a founding member of the Swedish Gynecologic Cancer Group (www.swegcg.se), a national research collaborative network. Further I head the gynecologic cancer biobank at Uppsala University (www.u-can.uu.se), which is a fruitful base for translational studies.

Nationally, I have played a key role in shaping Swedish National Guidelines, serving eight years on the ovarian cancer committee and currently chairing the endometrial cancer group. Under my leadership, we have implemented sentinel node procedures, molecular classification, and are now integrating FIGO 2023 staging.

I have an interest in improving global health, and during 2024 I spent two months in an hospital in Nepal, helping out with introducing laparoscopic surgery. We are currently working with a bilateral contract with Kenyatta National Hospital, Nairobi to exchange clinical and scientific skills.

I was instrumental in establishing Uppsala University Hospital as an ESGO Centre of Excellence in both ovarian and endometrial cancer surgery, and I actively contribute to the ESGO ovarian cancer database as a member of the SEC committee.

ESGO's mission to improve the quality of care, promote research, and foster education in gynecologic oncology resonates deeply with my professional values. I bring a strong track record of clinical excellence, research innovation, and organizational leadership. I would be honored to contribute to ESGO Council's work

Curriculum vitae

Name: Karin Glimskär Ståhlberg, M.D., Ph.D.

Date of Birth: August 11, 1971

Place of Birth: Spånga, Sweden

Citizenship: Swedish

Address: Dept. of Obstetrics and Gynecology

Uppsala University Hospital

751 85 Uppsala, Sweden

e-mail: karin.stalberg@kbh.uu.se

phone: 0046 768503922

University Degrees

- | | |
|------|---|
| 2023 | Senior Lecturer, Department for Women's and Children's Health, Uppsala University |
| 2018 | Associate Professor, Obstetrics and Gynecology, Uppsala University |
| 2008 | Doctor of Medical Sciences, Uppsala University, " <i>Prenatal ultrasound and X-ray-potentially adverse effects on the CNS</i> ". Thesis for Dissertation Obstetrics and Gynaecology, Uppsala University |
| 1996 | University Medical Degree, Karolinska Institute, Stockholm |

Medical Qualification

- | | |
|------|---|
| 2014 | Registered Subspecialist in Gynecologic Oncology Surgery |
| 2007 | Board certified Specialist in Obstetrics and Gynecology |
| 1998 | Licensed to Practice Medicine by the Swedish National Board of Health |

Clinical Positions

- | | |
|-----------|--|
| 2012-ong | Senior Consultant in Gynecologic Cancer Surgery, Uppsala University Hospital |
| 2012-ong | Director of Gynecologic Cancer surgery, Dept. of Obstetrics and Gynecology, Uppsala University Hospital |
| 2007-2012 | Consultant in Obstetrics and Gynecology, Dept. of Obstetrics and Gynecology, Uppsala University Hospital |
| 1999-2006 | Resident in Obstetrics and Gynecology Dept. of Obstetrics and Gynecology, Uppsala University Hospital |
| 1996-1998 | Internship, Sala/Västerås County Hospital |

University/Teaching Appointments

- | | |
|-----------|--|
| 2023-ong | Senior lecturer, Dept of Women's and Children's Health, Uppsala University |
| 2024-ong | Steering group, Research School for Clinical PhD Students/ UU |
| 2017-2018 | Senior Lecturer, Dept. of Women's and Children's Health, UU, 50% |
| 2008-ong | Affiliated researcher at the Department of Women's and Children's Health, UU |
| 2022 | Faculty opponent. Phd degree. Mihaela Asp. Lunds University |
| 2022-ong | Examination board. PhD degree. 5 occasions |

Supervision of PhD students, completed

- | | |
|------|---|
| 2022 | Main supervisor Björg Jonsdóttir, Dept of Women's and Children's Health, UU, Dissertation Jan 21, 2022 |
| 2021 | Co-supervisor Camilla Sköld, Dept of Immunology, genetics and pathology, UU: Dissertation June 5, 2022 |
| 2021 | Co-supervisor Madelene Olsen, Dept of Women's and Children's Health, Linköpings University; Dissertation Dec 10, 2021 |
| 2024 | Co-supervisor Johanna Norenhag, Dept of Women's and Children's Health, UU. Dissertation Okt 11, 2023 |

2025	Co-supervisor Maria Romare Strandh, Dept of Women's and Children's Health, UU, Dissertation June 2025
Supervision of PhD students, ongoing	
1	Main supervisor Chrysanthos Ioannou, Dept of Women's and Children's Health, UU: Registration 2022
2	Main supervisor Per Ehn, Dept of Women's and Children's Health, UU. Registration 2023
4	Co-supervisor Cecilia Malmsten, Institutionen för Kliniska Vetenskaper, Obstetrik och Gynecologi, Sahlgrenska Akademien, Göteborgs Universitet. 2023
5	Co-supervisor Alexandra Popa, Dept of Women's and Children's Health, Linköpings University 2025
6	Co-supervisor Oksana Vorobii, Dept of Women's and Children's Health, UU, 2025
Comissions of Trust	
2022-ong	Director of the Swedish National Steering Group for Management Guidelines for Endometrial Cancer
2013-ong	Member of the national research group "Swedish Gynecologic Cancer Group"
2012-ong	Head of U-CAN tumour biobank, (Uppsala Umeå Biobank Consortium), gynaecologic cancer.
2012-2019	Steering Committee, National Group for Guidelines for Ovarian Cancer
2017-2021	Head of Swedish Working group Gynecologic Cancer Surgery (Tumör-ARG, SFOG)
2003-2004	Chairwoman Society of Swedish residents in Obstetrics and Gynaecology
2002-2004	Board Member Swedish Society of Obstetrics and Gynecology
Administrative experience	
2024	ESGO (European Society of Gynecologic Oncology) Ovarian Cancer Database Steering Committe
Awards	
2023	Region Uppsala Research Award
2005	Best oral presentation, Annual Meeting, Swedish Society of Obstetrics and Gynecology
2001	Gemzell Award, Dept. Women's and Children's Health, Uppsala University
Research activities	
H-index 18	
Number of original scientific publications: 60	
Number of original scientific publications as first and last author: 28	
Number of review articles: 3	
Number of book chapters: 1	
Funding last five years, main applicant	
2024	Swedish Research Council, 1,1 billion sek. Monitoring and early detection of relapse in ovarian cancer using home-sampling and a multiplex protein biomarker test
2020	Regionala Forskningsrådet Mellansverige, 400 tkr, 2020, Clinical validation of a screening instrument for endometrial cancer in a high-risk population
Funding Co-applicant	

1. Swedish Research Council, 2024-2026, Prof. Marta Lomnytska, 9 billion sek
2. Swedish Cancer Foundation, Prof. Gyllensten, 2023-2025 6.8 billion sek
3. Swedish Research Council, Prof. Stefan Enroth, "Multi-omics characterization of tumour-tissue, plasma and cervicovaginal fluid for early detection of ovarian cancer" 2023-2026, 4.8 billion sek
4. Swedish Research Council, Professor Anna Wikman, for collaboration project WOMHER, 2020-2024, 1 600 000.
5. Swedish Cancer Foundation, Professor Anna Wikman, 2020-2023, 2 400 00

List of publications Karin Stålberg 2025-08

Original peer-reviewed articles

1. Hübinette M, Sundström-Poromaa I, Persson S, Elenis E, **Stålberg K**, Forslund M. *Polycystic ovary syndrome and the risk of ovarian tumours*. Gynecol Oncol. 2025 Jul 12;200:1-7. doi: 10.1016/j.ygyno.2025.07.005. PMID: 40652611
2. Moskov M, Hedlund Lindberg J, Lycke M, Ivansson E, Gyllensten U, Sundfeldt K, **Stålberg K**, Enroth S. *Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer*. Commun Med (Lond). 2025 Jun 12;5(1):230. doi: 10.1038/s43856-025-00945-0. PMID: 40506476
3. Karlsson E, Vorobii O, Silins I, Sundström Poromaa I, **Stålberg K**, Lomnytska M. *Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction*. Gynecol Oncol. 2025 Jun;197:121-128. doi: 10.1016/j.ygyno.2025.04.592. Epub 2025 May 8. PMID: 40344962
4. Bjurberg M, Hellman K, Säll TA, Staf C, Borgfeldt C, Holmberg E, Jönsson J, Lindahl G, Flöter Rådestad A, Sköld C, Bohlin KS, **Stålberg K**, Åvall-Lundqvist E, Kjølhede P, Dahm-Kähler P. *Validation of data quality in the Swedish quality register of gynecologic cancer for cervical cancer and vulvar cancer-a Swedish gynecologic cancer group (Swe-GCG) study*. Acta Obstet Gynecol Scand. 2025 Aug;104(8):1530-1538. doi: 10.1111/aogs.15152. Epub 2025 May 7. PMID: 40331784
5. Wedin M, **Stålberg K**, Ottander U, Åkesson Å, Lindahl G, Wodlin NB, Kjølhede P *Risk factors for lymph ascites after surgery for endometrial cancer and impact on lymphedema of the legs. A prospective longitudinal Swedish multicenter study*. Acta Obstet Gynecol Scand. 2025 Mar 4. doi: 10.1111/aogs.15077. PMID: 40035366
6. Ivansson E, Hedlund Lindberg J, **Stålberg K**, Sundfeldt K, Gyllensten U, Enroth S. *Large-scale proteomics reveals precise biomarkers for detection of ovarian cancer in symptomatic women*. S.Sci Rep. 2024 Jul 27;14(1):17288. doi: 10.1038/s41598-024-68249-2. PMID: 39068297
7. Romare Strandh M, Enebrink P, **Stålberg K**, Sörensdotter R, Ljungman L, Wikman A *Parenting under pressure: a cross-sectional questionnaire study of psychological distress, parenting concerns, self-efficacy, and emotion regulation in parents with cancer*. Acta Oncol. 2024 Jun 20;63:468-476. doi: 10.2340/1651-226X.2024.40404. PMID: 38910314
8. Norenhaag J, Edfeldt G, **Stålberg K**, Garcia F, Hugerth LW, Engstrand L, Fransson E, Du J, Schuppe-Koistinen I, Olovsson M. *Compositional and functional differences of the vaginal microbiota of women with and without cervical dysplasia*. Sci Rep. 2024 May 16;14(1):11183. doi: 10.1038/s41598-024-61942-2. PMID: 38755259
9. Dahm-Kähler P, Rådestad AF, Holmberg E, Borgfeldt C, Bjurberg M, Sköld C, Hellman K, Kjølhede P, **Stålberg K**, Åvall-Lundqvist E. *Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study*. Gynecol Oncol. 2024 Jul;186:69-76. doi: 10.1016/j.ygyno.2024.03.011. PMID: 38603954
10. Sköld C, Corvigno S, Dahlstrand H, Enblad G, Mezheyski A, Sundström-Poromaa I, **Stålberg K**, Tolf A, Glimelius I, Koliadi A. *Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer*. Cancer Causes Control. 2024 Aug;35(8):1101-1109. doi: 10.1007/s10552-024-01876-2. PMID: 38578428
11. Hedlund Lindberg J, Widgren A, Ivansson E, Gustavsson I, **Stålberg K**, Gyllensten U, Sundfeldt K, Bergquist J, Enroth S. *Toward ovarian cancer screening with protein biomarkers using dried, self-sampled cervico-vaginal fluid* iScience. 2024 Jan 24;27(2):109001. doi: 10.1016/j.isci.2024.109001. PMID: 38352226

12. Romare Strandh M, Hovén E, Sörensdotter R, **Stålberg K**, Enebrink P, Ljungman L, Wikman A. *The Complexity of Being a Parent in the Hospital and a Patient at Home: A Qualitative Study on Parenting Concerns and Challenges Among Parents With Cancer*. Cancer Nurs. 2023 Sep 21. doi: 10.1097/NCC.0000000000001276. PMID: 37731179
13. Álvez MB, Edfors F, von Feilitzen K, Zwahlen M, Mardinoglu A, Edqvist PH, Sjöblom T, Lundin E, Rameika N, Enblad G, Lindman H, Höglund M, Hesselager G, **Stålberg K**, Enblad M, Simonson OE, Häggman M, Axelsson T, Åberg M, Nordlund J, Zhong W, Karlsson M, Gyllensten U, Ponten F, Fagerberg L, Uhlén M. *Next generation pan-cancer blood proteome profiling using proximity extension assay*. Nat Commun. 2023 Jul 18;14(1):4308. doi: 10.1038/s41467-023-39765-y. PMID: 37463882
14. Jónsdóttir B, Wikman A, Sundström Poromaa I, **Stålberg K**. *Advanced gynecological cancer: Quality of life one year after diagnosis* PLoS One. 2023 Jun 23;18(6):e0287562. doi: 10.1371/journal.pone.0287562. PMID: 37352193
15. Bratulic S, Limeta A, Dabestani S, Birgisson H, Enblad G, **Stålberg K**, Hesselager G, Häggman M, Höglund M, Simonson OE, Stålberg P, Lindman H, Bång-Rudenstam A, Ekstrand M, Kumar G, Cavarretta I, Alfano M, Pellegrino F, Mandel-Clausen T, Salanti A, Maccari F, Galeotti F, Volpi N, Daugaard M, Belting M, Lundstam S, Stierner U, Nyman J, Bergman B, Edqvist PH, Levin M, Salonia A, Kjölhede H, Jonasch E, Nielsen J, Gatto F. *Noninvasive detection of any-stage cancer using free glycosaminoglycans*. Proc Natl Acad Sci U S A. 2022 Dec 13;119(50):e2115328119. doi: 10.1073/pnas.2115328119. PMID: 36469776
16. Enroth S, Ivansson E, Lindberg JH, Lycke M, Bergman J, Reneland A, **Stålberg K***, Sundfeldt K*, Gyllensten U*. *Data-driven analysis of a validated risk score for ovarian cancer identifies clinically distinct patterns during follow-up and treatment*. Commun Med (Lond). 2022 Oct 1;2:124. doi: 10.1038/s43856-022-00193-6. eCollection 2022. PMID: 36196264
17. Bjersand K, Blom K, Poromaa IS, **Stålberg K**, Lejon AM, Bäckman F, Nyberg Å, Andersson C, Larsson R, Nygren P. *Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome*. Int J Oncol. 2022 Oct;61(4):128. doi: 10.3892/ijo.2022.5418. PMID: 36082820
18. Flöter Rådestad A, Dahm-Kähler P, Holmberg E, Bjurberg M, Hellman K, Högberg T, Kjölhede P, Marcickiewicz J, Rosenberg P, **Stålberg K**, Åvall-Lundqvist E, Borgfeldt C. *Long-term incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group (SweGCG) study*. Acta Obstet Gynecol Scand. 2022 Aug;101(8):923-930. doi: 10.1111/aogs.14385. PMID: 35624547
19. Gyllensten U, Hedlund-Lindberg J, Svensson J, Manninen J, Öst T, Ramsell J, Åslin M, Ivansson E, Lomnytska M, Lycke M, Axelsson T, Liljedahl U, Nordlund J, Edqvist PH, Sjöblom T, Uhlén M, **Stålberg K**, Sundfeldt K, Åberg M, Enroth S. *Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer*. Cancers (Basel). 2022 Mar 30;14(7):1757. doi: 10.3390/cancers14071757. PMID: 35406529;
20. Marcickiewicz J, Åvall-Lundqvist E, Holmberg ECV, Borgfeldt C, Bjurberg M, Dahm-Kähler P, Flöter-Rådestad A, Hellman K, Högberg T, Rosenberg P, Kjölhede P, **Stålberg K**. *The wait time to primary surgery in endometrial cancer - impact on survival and predictive factors: a population-based SweGCG study*. Acta Oncol. 2022 Jan;61(1):30-37. doi: 10.1080/0284186X.2021.1992006. PMID: 34736369.
21. Olsson C, Wilde Larsson B, Larsson M, Holmberg E, Marcickiewicz J, Tholander B, Flöter-Rådestad A, Bjurberg M, Dahm-Kähler P, Hellman K, Kjölhede P, **Stålberg K**, Högberg T, Åvall Lundqvist E, Borgfeldt C. *Adaption of the Quality from the Patient's Perspective Instrument for Use in Assessing Gynecological Cancer Care and Patients' Perceptions of Quality Care Received*. Cancer Care Research Online: January 2022. Volume 2. p e019 doi: 10.1097/CR9.0000000000000019
22. Sköld C, Koliadi A, Enblad G, **Stålberg K**, Glimelius I. *Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes*. Int J Cancer. 2022 Mar 1;150(5):773-781. doi: 10.1002/ijc.33844. PMID: 34648676.
23. Wedin M, **Stålberg K**, Marcickiewicz J, Ahlner E, Åkesson Å, Lindahl G, Wodlin NB, Kjölhede P; LASEC study group. *Impact of lymphadenectomy and lymphoedema on health-*

related quality of life 1 year after surgery for endometrial cancer. A prospective longitudinal multicentre study. BJOG. 2022 Feb;129(3):450-460. doi: 10.1111/1471-0528.16870. PMID: 34437763.

24. Wedin M, **Stålberg K**, Marcickiewicz J, Ahlner E, Ottander U, Åkesson Å, Lindahl G, Wodlin NB, Kjølhed P; LASEC study group. *Risk factors for lymphedema and method of assessment in endometrial cancer: a prospective longitudinal multicenter study.* Int J Gynecol Cancer. 2021 Nov;31(11):1416-1427. doi: 10.1136/ijgc-2021-002890. Epub 2021 Oct 5. PMID: 34610970.
25. Borgfeldt C, Holmberg E, Marcickiewicz J, **Stålberg K**, Tholander B, Lundqvist EÅ, Flöter-Rådestad A, Bjurberg M, Dahm-Kähler P, Hellman K, Hjerpe E, Kjølhed P, Rosenberg P, Högborg T. *Survival in endometrial cancer in relation to minimally invasive surgery or open surgery - a Swedish Gynecologic Cancer Group (SweGCG) study.* BMC Cancer. 2021 Jun 2;21(1):658. doi: 10.1186/s12885-021-08289-3. PMID: 34078319; PMCID: PMC8170953.
26. Dahm-Kähler P, Holmberg E; Holtenman M; Flöter Rådestad A; ... **K Stålberg**. *Implementation of National Guidelines Increased Survival in Advanced Ovarian Cancer - A population-based nationwide SweGCG study.* Gynecol Oncol. 2021 Feb 10:S0090-8258(21)00059-7. doi: 10.1016/j.ygyno.2021.01.012. PMID: 33581846
27. Lomnyska M, Karlsson E, Jonsdottir B, Lejon AM, **Stålberg K**, Poromaa IS, Silins I, Graf W. *Peritoneal cancer index predicts severe complications after ovarian cancer surgery.* Eur J Surg Oncol. 2021 May 13:S0748-7983(21)00495-9. doi: 10.1016/j.ejso.2021.05.019. Online ahead of print. PMID: 34053777
28. Jónsdóttir B, Ripoll MA, Bergman A, Silins I, Poromaa IS, Ahlström H, **Stålberg K**. *Validation of 18F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of peritoneal carcinomatosis in ovarian and endometrial cancer -a pilot study.* Cancer Imaging. 2021 Apr 13;21(1):34. doi: 10.1186/s40644-021-00399-2. PMID: 33849649
29. Ljungman L, Köhler M, Hovén E, **Stålberg K**, Mattsson E, Wikman A. *"There should be some kind of checklist for the soul"- A qualitative interview study of support needs after end of treatment for gynecologic cancer in young women.* Eur J Oncol Nurs. 2021 Jun;52:101927. doi: 10.1016/j.ejon.2021.101927. PMID: 33780760
30. Jónsdóttir B, Marcickiewicz J, Borgfeldt C, Bjurberg M, Dahm-Kähler P, Flöter-Rådestad A, Hellman K, Holmberg E, Kjølhed P, Rosenberg P, Tholander B, Åvall-Lundqvist E, **Stålberg K**, Högborg T. *Preoperative and intraoperative assessment of myometrial invasion in endometrial cancer-A Swedish Gynecologic Cancer Group (SweGCG) study.* Acta Obstet Gynecol Scand. 2021 Aug;100(8):1526-1533. doi: 10.1111/aogs.14146. PMID: 33721324
31. Dahm-Kähler P, Holmberg E, Holtenman M, Rådestad AF, Borgfeldt C, Hjerpe E, Marcickiewicz J, Bjurberg M, Tholander B, Hellman K, Kjølhed P, Högborg T, Rosenberg P, Åvall-Lundqvist E, **Stålberg K**. *Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.* Gynecol Oncol. 2021 Apr;161(1):244-250. Doi: 10.1016/j.ygyno.2021.01.012. PMID: 33581846
32. Mattsson E, Lisa Ljungman, Kim Einhorn, Inger Sundström-Poromaa, **Stålberg K**, Anna Wikman. *Perceptions of care after end-of-treatment among younger women with different gynecologic cancer diagnoses- A qualitative analysis of written responses submitted via a survey* BMC Womens Health. 2020 Dec 22;20(1):276. doi: 10.1186/s12905-020-01133-z.PMID: 33353541
33. Hellman K, Bjurberg M, Borgfeldt C, Dahm-Kähler P, Flöter Rådestad A, Hjerpe E, Högborg T, Marcickiewicz J, Rosenberg P, **Stålberg K**, Tholander B, Kjølhed P, Åvall-Lundqvist. *Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study.* Gynecol Oncol. 2020 Sep 25:S0090-8258(20)33920-2. doi: 10.1016/j.ygyno.2020.09.027. PMID: 32988623
34. Wedin M, **Stålberg K**, Marcickiewicz J, Ahlner E, Åkesson Å, Lindahl G, Kjølhed P; LASEC study group. *Incidence of lymphedema in the lower limbs and lymphocyst formation within one year of surgery for endometrial cancer: A prospective longitudinal multicenter study.* Gynecol Oncol. 2020 Oct;159(1):201-208. doi: 10.1016/j.ygyno.2020.07.014. PMID: 32763108

35. Gyllensten U, Bosdotter Enroth S, **Stålberg K**, Sundfeldt K, Enroth S. *Preoperative Fasting and General Anaesthesia Alter the Plasma Proteome*. *Cancers (Basel)*. 2020 Aug 27;12(9):2439. doi: 10.3390/cancers12092439. PMID: 32867270
36. Jónsdóttir B, Lomnytska M, Poromaa IS, Silins I, **Stålberg K**. *The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer*. *Ann Surg Oncol*. 2020 May 29. doi: 10.1245/s10434-020-08649-6. PMID: 32472412
37. Bjurberg M, Holmberg E, Borgfeldt C, Flöter-Rådestad A, Dahm-Kähler P, Hjerpe E, Högberg T, Kjølhede P, Marcickiewicz J, Rosenberg P, **Stålberg K**, Tholander B, Hellman K, Åvall-Lundqvist E. *Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study*. *Gynecol Oncol*. 2019 Aug 30 PMID:31477283
38. **Stålberg K**, Bjurberg M, Borgfeldt C, Carlson J, Dahm-Kähler P, Flöter-Rådestad A, Hellman K, Hjerpe E, Holmberg E, Kjølhede P, Marcickiewicz J, Rosenberg P, Tholander B, Åvall-Lundqvist E, Högberg T. *Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study*. *Acta Oncol*. 2019 Aug 2:1-6. doi: 10.1080/0284186X.2019.1643036. PMID:31373248
39. Enroth S, Berggrund M, Lycke M, Broberg J, Lundberg M, Assarsson E, Olovsson M, **Stålberg K**, Sundfeldt K, Gyllensten U. *High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer* *Communications Biology*, volume 2, Article number: 221 (2019) June 20
40. Alfonzo E, Wallin E, Ekdahl L, Staf C, Rådestad AF, Reynisson P, **Stålberg K**, Falconer H, Persson J, Dahm-Kähler P. *No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study*. *Eur J Cancer*. 2019 Jul;116:169-177. doi: 10.1016/j.ejca.2019.05.016. PMID:31200323
41. Falconer H, Palsdottir K, **Stålberg K**, Dahm-Kähler P, Ottander U, Lundin ES, Wijk L, Kimmig R, Jensen PT, Zahl Eriksson AG, Mäenpää J, Persson J, Salehi S. *Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial*. *Int J Gynecol Cancer*. 2019 Jul;29(6):1072-1076, PMID:31203203
42. Berggrund M, Enroth S, Lundberg M, Assarsson E, **Stålberg K**, Lindquist D, Hallmans G, Grankvist K, Olovsson M, Gyllensten U. *Identification of candidate plasma protein biomarkers for cervical cancer using the multiplex proximity extension assay*. *Mol Cell Proteomics*, 2019 Apr;18(4):735-743. doi: 10.1074/mcp.RA118.001208. PMID: 30692274
43. Halldorsdottir S, Dahlstrand H, **Stålberg K**. *Gynecologists are afraid of prescribing hormone replacement to endometrial/ovarian cancer survivors despite national guidelines-a survey in Sweden*. *Ups J Med Sci*. 2018;123(4):225-229. PMID: 30526173
44. Enroth S, Berggrund M, Lycke M, Lundberg M, Assarsson E, Olovsson M, **Stålberg K**, Sundfeldt K, Gyllensten U. *A two-step strategy for identification of plasma protein biomarkers for endometrial and ovarian cancer*. *Clin Proteomics* 2018;15:38. PMID: 30519148
45. Mattsson E, Einhorn K, Ljungman L, Sundström-Poromaa I, **Stålberg K**, Wikman A. *Women treated for gynaecological cancer during young adulthood - A mixed-methods study of perceived psychological distress and experiences of support from health care following end-of-treatment*. *Gynecol Oncol*. 2018 PMID: 29588102
46. Hjerpe E, Staf C, Dahm-Kähler P, **Stålberg K**, Bjurberg M, Holmberg E, Borgfeldt C, Tholander B, Hellman K, Kjølhede P, Högberg T, Rosenberg P, Åvall-Lundqvist E. *Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study*. *Acta Oncol* 2018;57(3):331-337. PMID: 29130381
47. Rosenberg P, Kjølhede P, Staf C, Bjurberg M, Borgfeldt C, Dahm-Kähler P, Hellman K, Hjerpe E, Holmberg E, **Stålberg K**, Tholander B, Åvall Lundqvist E, Högberg T. *Data quality in the Swedish Quality Register of Gynecologic Cancer - a Swedish Gynecologic Cancer Group (SweGCG) study*. *Acta Oncol* 2018;57(3):346-353. PMID: 28828920

48. Glimelius B, Melin B, Enblad G , Alafuzoff I , Beskow A, Ahlström H , Bill-Axelsson A , Birgisson H, Björ O, Edqvist PH, Hansson T, Helleday T , Hellman P , Henriksson K, Hesselager G , Hultdin M , Häggman M, Höglund M , Jonsson H , Larsson C, Lindman H , Ljuslinder I ,Mindus S, Nygren P , Pontén F, Riklund K, Rosenquist R, Sandin F, Schwenk JM, Stenling R, **Stålberg K**, Stålberg P, Thellenberg Karlsson C, Bergh A *U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden*. Acta Oncol 2017;1-8. PMID: 286315338
49. **Stålberg K** , Kjølhede P, Bjurberg M , Borgfeldt C , Dahm-Kähler P , Falconer H, Holmberg E ,Staf C, Tholander B, Åvall-Lundqvist E , Rosenberg P, Högberg T *Risk factors for lymph node metastases in women with endometrial cancer: A populationbased, nation-wide register study - On behalf of the Swedish gynecological cancer group (SweGCG)*. Int J Cancer 2017;140(12)(Jun 15):2693-2700. PMID: 28340503
50. Dahm-Kähler P, Borgfeldt C , Holmberg E , Staf C, Falconer H, Bjurberg M , Kjølhede P , Rosenberg P, **Stålberg K** , Högberg T, Åvall-Lundqvist E *Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG)*. Gynecol Oncol. 2016 PMID: 27817932
51. **Stålberg K**, Crona J , Razmara M, Taslica D, Skogseid B , Stålberg P *An Integrative Genomic Analysis of Formalin Fixed Paraffin-Embedded Archived Serous Ovarian Carcinoma Comparing Long-term and Short-term Survivors*. Int J Gynecol Cancer 2016 PMID: 27177282
52. **Stålberg K**, Svensson T, Lönn S, Kieler H. *The influence of comorbidity on mortality in ovarian cancer patients*. Gynecol Oncol. 2014;133(2):298-303. PMID: 24582801
53. Billström E, Sundström-Poromaa I, **Stålberg K** , Asplund A, Hellberg D *Socioeconomic characteristics, housing conditions and criminal offences among women with cervical neoplasia*. Acta Obstet Gynecol Scand 2013;92(8):888-94. PMID: 23590762
54. **Stålberg K** , Svensson T, Granath F, Kieler H, Tholander B, Lönn S *Evaluation of prevalent and incident ovarian cancer co-morbidity*. Br J Cancer 2012;106(11):1860-5. PMID: 22549177
55. **Stålberg K** , Haglund B, Strömberg B, Kieler H. *Prenatal exposure to medicines and the risk of childhood brain tumor*. Cancer Epidemiol 2010;34(4):400-4. PMID: 20510665
56. **Stålberg K** , Axelsson O , Haglund B, Hultman CM , Lambe M , Kieler H. *Prenatal ultrasound exposure and children's school performance at age 15-16: follow-up of a randomized controlled trial*. Ultrasound Obstet Gynecol 2009;34(3):297-303. PMID: 19705400
57. **Stålberg K** , Haglund B, Axelsson O , Cnattingius S, Pfeifer S, Kieler H. *Prenatal ultrasound and the risk of childhood brain tumour and its subtypes*. Br J Cancer 2008;98(7):1285-7. PMID: 18349848
58. **Stålberg K** , Haglund B, Axelsson O , Cnattingius S, Pfeifer S, Kieler H. *Prenatal X-ray exposure and childhood brain tumours: a population-based case-control study on tumour subtypes*. Br J Cancer 2007;97(11):1583-7. PMID: 17971773
59. **Stålberg K** , Haglund B, Axelsson O , Cnattingius S, Hultman CM , Kieler H. *Prenatal ultrasound scanning and the risk of schizophrenia and other psychoses*. Epidemiology 2007;18(5):577-82. PMID: 17700245
60. **Stålberg K** , Bodestedt A, Lyrenäs S, Axelsson O *A narrow pelvic outlet increases the risk for emergency cesarean section*. Acta Obstet Gynecol Scand 2006;85(7):821-4. PMID: 16817080

Reviews, book chapters etc.

1. Ebrahimi S, Lundström E, Batasin SJ, Hedlund E, **Stålberg K**, Ehman EC, Sheth VR, Iranpour N, Loubrie S, Schlein A, Rakow-Penner R. *Application of PET/MRI in Gynecologic Malignancies*. Cancers (Basel). 2024 Apr 12;16(8):1478. doi: 10.3390/cancers16081478. PMID: 38672560

2. Romare Strandh M, Hovén E, Sörensdotter R, **Stålberg K**, Enebrink P, Ljungman L, Wikman A *Psychosocial interventions targeting parenting distress among parents with cancer - A systematic review and narrative synthesis of available interventions*. Crit Rev Oncol Hematol. 2023 Nov;191:104119. doi: 10.1016/j.critrevonc.2023.104119. PMID: 37683815
3. Salehi S, **Stålberg K**, Marcickiewicz J, Rosenberg P, Falconer H. Increasingly better diagnosis and treatment of endometrial cancer. Lakartidningen. 2015 Dec 8;112. pii: DLDT. Review. Swedish.
4. Book chapter : Endometrial Cancer, Gynekologi, Studentlitteratur ISBN. 9789144144191. Date 2022-01-19, 3d Edition
5. Website: Internetmedicin. Chapter Endometrial Cancer . Date 2021-09-28
<https://www.internetmedicin.se/behandlingsoversikter/onkologi/endometriecancer/>
6. Website: Internetmedicin. Chapter Uterine sarcomas. Date 2022-05-20